Eric Venker Sells 100,000 Shares of Roivant Sciences Ltd. (NASDAQ:ROIV) Stock

Roivant Sciences Ltd. (NASDAQ:ROIV) COO Eric Venker sold 100,000 shares of the business’s stock in a transaction that occurred on Friday, December 20th. The stock was sold at an average price of $11.49, for a total transaction of $1,149,000.00. Following the sale, the chief operating officer now directly owns 595,580 shares in the company, valued at $6,843,214.20. The trade was a 14.38 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Eric Venker also recently made the following trade(s):

• On Wednesday, November 20th, Eric Venker sold 100,000 shares of Roivant Sciences stock. The stock was sold at an average price of $11.32, for a total transaction of $1,132,000.00.
• On Monday, October 21st, Eric Venker sold 100,000 shares of Roivant Sciences stock. The stock was sold at an average price of $11.65, for a total transaction of $1,165,000.00.

Roivant Sciences Stock Down 1.7 %

Roivant Sciences stock opened at $11.80 on Friday. Roivant Sciences Ltd. has a 12-month low of $9.69 and a 12-month high of $13.06. The firm’s fifty day moving average is $11.91 and its 200 day moving average is $11.52. The company has a market capitalization of $8.59 billion, a PE ratio of 2.09 and a beta of 1.25.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. nVerses Capital LLC acquired a new position in shares of Roivant Sciences during the 2nd quarter valued at $34,000. Gladius Capital Management LP acquired a new position in shares of Roivant Sciences during the 3rd quarter valued at $35,000. Point72 Hong Kong Ltd acquired a new position in Roivant Sciences during the second quarter worth $36,000. US Bancorp DE raised its holdings in Roivant Sciences by 146.5% during the third quarter. US Bancorp DE now owns 3,278 shares of the company’s stock worth $38,000 after buying an additional 1,948 shares during the last quarter. Finally, Quarry LP acquired a new position in Roivant Sciences during the second quarter worth $53,000. Institutional investors and hedge funds own 64.76% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on the stock. Bank of America boosted their price target on shares of Roivant Sciences from $12.00 to $12.50 and gave the stock a “neutral” rating in a research report on Wednesday, September 11th. Cantor Fitzgerald restated an “overweight” rating on shares of Roivant Sciences in a research report on Thursday, September 19th. Finally, HC Wainwright restated a “buy” rating and issued a $18.00 price target on shares of Roivant Sciences in a research report on Wednesday, November 13th. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Roivant Sciences has an average rating of “Moderate Buy” and a consensus price target of $17.93.

About Roivant Sciences

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.